Skip directly to page options Skip directly to A-Z link
Volume 20, Number 1—January 2014
Research

Dynamic Modeling of Cost-effectiveness of Rotavirus Vaccination, Kazakhstan

Birgitte Freiesleben de BlasioComments to Author , Elmira Flem, Renat Latipov, Ajnagul Kuatbaeva, and Ivar Sønbø Kristiansen
Author affiliations: Norwegian Institute of Public Health, Oslo, Norway (B. Freiesleben de Blasio, E. Flem); University of Oslo, Norway (B. Freiesleben de Blasio, I.S. Kristiansen); Research Institute of Virology, Tashkent, Republic of Uzbekistan (R. Latipov); Scientific-Practical Centre of Epidemiologic Surveillance, Almaty, Republic of Kazakhstan (A. Kuatbaeva)

Main Article

Table 3

Estimates of projected direct and indirect costs associated with rotavirus disease and rotavirus vaccination, Kazakhstan

Item (per case)
 Cost estimates in 2012 US dollars
Direct
 Indirect
 Total
 Reference/source
Rotavirus death 543.33 67,254.13 67,799.46 (8)
Severe case (inpatient care) 364.36 181.47 545.83 (8)
Moderate case (outpatient care) 32.43 65.57 98.00 (8)
Mild case (homecare) 3.49 21.86 25.35 (8)
Cost of vaccine per dose, base case 43.00 0 43.00 Authors’ assumption
Cold chain upgrade (total first year) 237,300 0 237,300 KMoH
Training costs (first year) 120,096 0 120,096 KMoH
Annual cost of cold chain and training
 22,037.74
 0
 22,037.74
 KMoH
*KMoH, Kazakh Ministry of Health.

Main Article

Page created: January 03, 2014
Page updated: January 03, 2014
Page reviewed: January 03, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external